211108-50-8

Basic information

• Product Name: TERT-BUTYL 3-FLUORO-4-OXOPIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 3-FLUORO-4-OXOPIPERIDINE-1-CARBOXYLATE;4-Boc-Piperidinone,3-fluoro;3-Fluoro-4-boc- Piperidinone;tert-Butyl 3-fluoro-4-oxopiperidin-1-carboxylate;3-Fluoro-4-oxopiperidine-1-carboxylic acid tert-butyl ester;N-t-BOC-5-Fluoropiperidin-4-one;3-Fluoropiperidin-4-one, N-BOC protected;tert-Butyl 3-fluoro-4-oxopiperidine-1-carboxylate, 1-(tert-Butoxycarbonyl)-3-fluoro-4-oxopiperidine
• CAS NO: 211108-50-8
• Molecular Formula: C₁₀H₁₆FNO₃
• Molecular Weight: 217.24
• Product Categories: kl
• Mol File: 211108-50-8.mol
• Article Data: 45

Chemical Properties

• Melting Point: 88-90℃
• Boiling Point: 288.719 °C at 760 mmHg
• Flash Point: 128.413 °C
• Appearance: /
• Density: 1.152 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -3.61±0.40(Predicted)
• CAS DataBase Reference: TERT-BUTYL 3-FLUORO-4-OXOPIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-FLUORO-4-OXOPIPERIDINE-1-CARBOXYLATE(211108-50-8)
• EPA Substance Registry System: TERT-BUTYL 3-FLUORO-4-OXOPIPERIDINE-1-CARBOXYLATE(211108-50-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36-52
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 211108-50-8(Hazardous Substances Data)

Usage

General Description

TERT-BUTYL 3-FLUORO-4-OXOPIPERIDINE-1-CARBOXYLATE is an organic compound that comes from the piperidine class of chemicals. Piperidines are a part of many pharmaceuticals and fine chemicals. It contains the substructures, or moieties, of an oxopiperidine, a tertiary butyl ester, and a fluorine atom. As a fluorinated compound, it can participate in various chemical reactions that are associated with fluorine. The main feature of this chemical is the 3-fluoro-4-oxopiperidin-1-yl moiety, which suggests that it could have potential uses as a building block in the synthesis of more complex molecules. However, detailed information about its properties and uses are limited, suggesting that it may be primarily a specialty or research chemical.

InChI:InChI=1/C10H16FNO3/c1-10(2,3)15-9(14)12-5-4-8(13)7(11)6-12/h7H,4-6H2,1-3H3

Upstream product

• 373604-27-4 C₁₃H₂₇NO₃Si 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 

Downstream Products

• 955029-44-4 (anti)-3-fluoro-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 1070896-84-2 (anti)-3-fluoro-4-methanesulfonyloxypiperidine-1-carboxylic acid tert-butyl ester 
• 907572-24-1 tert-butyl (3S,4R)-4-(benzylamino)-3-fluoro-piperidine-1-carboxylate 
• 907572-28-5 tert-butyl-(3R,4S)-4-(benzylamino)-3-fluoro-piperidine-1-carboxylate 
• 850606-19-8 4,4-diphenyl-3-fluoro-piperidine 
• 211108-52-0 (±)-cis-4-benzylamino-3-fluoropiperidine-1-carboxylic acid tert-butyl ester 
• 211108-52-0 trans-4-benzylamino-1-tert-butoxycarbonyl-3-fluoropiperidine 

Relevant articles and documents

Discovery of SARxxxx92, a pan-PIM kinase inhibitor, efficacious in a KG1 tumor model

N-substituted azaindoles were discovered as potent pan-PIM inhibitors. Lead optimization, guided by structure and focused on physico-chemical properties allowed us to solve inherent hERG and permeability liabilities, and provided compound 27, which subseq

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy R1, R2, R4, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.